MY133230A - Combination of no synthase inhibitor(s) and metabolic antioxidant(s) - Google Patents

Combination of no synthase inhibitor(s) and metabolic antioxidant(s)

Info

Publication number
MY133230A
MY133230A MYPI20001265A MYPI20001265A MY133230A MY 133230 A MY133230 A MY 133230A MY PI20001265 A MYPI20001265 A MY PI20001265A MY PI20001265 A MYPI20001265 A MY PI20001265A MY 133230 A MY133230 A MY 133230A
Authority
MY
Malaysia
Prior art keywords
thiol groups
many
combination
metabolic antioxidant
synthase inhibitor
Prior art date
Application number
MYPI20001265A
Inventor
De Lassauniere Pierre- Etienne Chabrier
Jeremiah Harnett
Michel Auguet
Original Assignee
Soc De Conseils De Recherches Et D Applications Scientifiques S C R A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soc De Conseils De Recherches Et D Applications Scientifiques S C R A S filed Critical Soc De Conseils De Recherches Et D Applications Scientifiques S C R A S
Publication of MY133230A publication Critical patent/MY133230A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

THE INVENTION RELATES TO A PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, ONE OR MANY SUBSTANCE (S) WHICH INTERFERE (S) WITH THE SYNTHESIS OF NITROGEN MONOXIDE BY INHIBITION OF NO SYNTHASE AND ONE OR MANY METABOLIC ANTIOXIDANT(S) POSSESSING AT LEAST TWO THIOL GROUPS AND WHICH INTERVENE (S) IN THE REDOX STATUS OF THIOL GROUPS, AND OPTIONALLY A PHARMACEUTICALLY ACCEPTABLE SUPPORT. THE INVENTION ALSO RELATES TO A PRODUCT CONTAINING ONE OR MANY NO SYNTHASE INHIBITORY SUBSTANCE (S) AND ONE OR MANY METABOLIC ANTIOXIDANT(S) POSSESSING AT LEAST TWO THIOL GROUPS WHICH INTERVENE (S) IN THE REDOX STATUS OF THIOL GROUPS, AS COMBINATION PRODUCT, IN SEPARATED FORM, OF THESE ACTIVE INGREDIENTS
MYPI20001265A 1999-04-02 2000-03-29 Combination of no synthase inhibitor(s) and metabolic antioxidant(s) MY133230A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9904134A FR2791571B1 (en) 1999-04-02 1999-04-02 ASSOCIATION OF NO SYNTHASE INHIBITOR (S) AND METABOLIC ANTIOXIDANT (S)

Publications (1)

Publication Number Publication Date
MY133230A true MY133230A (en) 2007-10-31

Family

ID=9543945

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20001265A MY133230A (en) 1999-04-02 2000-03-29 Combination of no synthase inhibitor(s) and metabolic antioxidant(s)

Country Status (9)

Country Link
EP (1) EP1169005A2 (en)
JP (1) JP2002541077A (en)
AR (1) AR023219A1 (en)
AU (1) AU3663700A (en)
CA (1) CA2365500A1 (en)
FR (1) FR2791571B1 (en)
MY (1) MY133230A (en)
NO (1) NO20014770L (en)
WO (1) WO2000059448A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816509B1 (en) * 2000-11-15 2004-02-06 Sod Conseils Rech Applic ASSOCIATION OF CALPAIN INHIBITORS AND OXYGEN REACTIVE TRAPS
US6476073B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating a hangover by enhancing the effectiveness of the human immune system
WO2004073623A2 (en) * 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
DE602005012089D1 (en) 2005-08-04 2009-02-12 Extarma Ag Liquid composition containing arginine and alpha-lipoic acid to improve sexual function
WO2009111037A2 (en) * 2008-03-04 2009-09-11 Indigene Pharmaceuticals Inc. Compositions and methods for treating nos-associated diseases
JP2011521908A (en) * 2008-05-09 2011-07-28 デューク ユニバーシティ Treatment of diseases based on the finding that thioredoxin regulates nitric oxide release in cells
TWI592156B (en) * 2011-10-04 2017-07-21 艾可達醫療公司 Methods for treating a stroke-related sensorimotor impairment using aminopyridines
US20150025147A1 (en) * 2012-03-02 2015-01-22 Kyowa Hakko Bio Co., Ltd Enhancer for eating activity and/or gastrointestinal activity
JP6509112B2 (en) * 2012-07-03 2019-05-08 プラブダ，ジェイ Methods for the treatment, diagnosis and / or monitoring of the progression of oxo related conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4630M (en) * 1965-06-09 1966-11-28
ZA716628B (en) * 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
US5091180A (en) * 1987-11-20 1992-02-25 Administrators Of The Tulane Educational Fund Protection against rhabdomyolysis-induced nephrotoxicity
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5852058A (en) * 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
GB9404400D0 (en) * 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
DE4420102A1 (en) * 1994-06-09 1995-12-14 Asta Medica Ag Combination prepns. contg. alpha-liponic acid or its metabolites
AU5317296A (en) * 1995-03-24 1996-10-16 Francis V. Defeudis Methods for treating conditions associated with excess nitri c oxide
US5951990A (en) * 1995-05-15 1999-09-14 Avon Products, Inc. Ascorbyl-phosphoryl-cholesterol
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
AU8768098A (en) * 1997-08-04 1999-02-22 Christopher J. Berry Method of treating disease using a tocotrienol and alpha-lipoic acid r derivatives or an ester thereof
AU759467B2 (en) * 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent

Also Published As

Publication number Publication date
FR2791571B1 (en) 2002-10-04
CA2365500A1 (en) 2000-10-12
WO2000059448A2 (en) 2000-10-12
FR2791571A1 (en) 2000-10-06
AR023219A1 (en) 2002-09-04
EP1169005A2 (en) 2002-01-09
NO20014770D0 (en) 2001-10-01
AU3663700A (en) 2000-10-23
WO2000059448A3 (en) 2001-03-08
JP2002541077A (en) 2002-12-03
NO20014770L (en) 2001-11-23

Similar Documents

Publication Publication Date Title
AU9163701A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
UA86413C2 (en) Normal;heading 1;heading 2;SUGAR COATING AND SOLID DOSAGE FORM CONTAINING THEREOF
CA2326485A1 (en) Anticancer compositions
BG106030A (en) Pharmaceutical composition
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
HRP20031003A2 (en) 4'-substituted nukleosides
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TW200514772A (en) Novel tetrahydropyridine derivatives
WO2004074266A8 (en) Hiv inhibiting 1,2,4-triazines
HUP0200623A3 (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors and pharmaceutical compositions containing them
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
WO2004078105A3 (en) Fondaparinux sodium composition of high purity, method for production of said composition and pharmaceutical compositions containing the same as active ingredient
AU3287200A (en) Composition comprising isoquercetin and ascorbic acid in a sustained release form
AU2061702A (en) Combination of catechin and quercetin for pharmaceutical or dietary use
WO2002070464A3 (en) Hydrazones and their therapeutic use
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MY133230A (en) Combination of no synthase inhibitor(s) and metabolic antioxidant(s)
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
AU2001286003A1 (en) Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
AU2001289714A1 (en) Benzofuran derivatives and their use as antibacterial agents
WO2002008222A3 (en) HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1